People
Li Qi
Phrontline Biopharma-affiliated co-author of the AACR 2026 research abstract on TJ106, an investigational HER2-targeting antibody-drug conjugate with two cytotoxic payloads.
Roles
Phrontline Biopharma
CurrentResearch Team (AACR 2026 author)